Year All202420232022202120202019 Jun 11, 2020 Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease Mar 23, 2020 Verve Therapeutics’ CEO Sekar Kathiresan to Speak at Wall Street Journal Health Forum Oct 03, 2019 Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer Oct 02, 2019 Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit Sep 16, 2019 Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board May 07, 2019 Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV
Jun 11, 2020 Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease
Oct 03, 2019 Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer
Sep 16, 2019 Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board
May 07, 2019 Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV
